These dual inhibitors may effectively shutdown PI3K/AKT signalling in cancers with PIK3CA and/or PIK3R1 mutations, PTEN loss, and RTK-dependent activation, all features that embody a large number of GBMs. Here, PIK3CA is linked to cancer.